natgillin/translations-raw huggingface dataset:
Common (may affect up to 1 in 10 people): oral infections, wound infection, reduced number of blood cells (neutropenia, thrombocytopenia, lymphopenia, leukopenia), increased sugar in the blood, loss of weight, change in mental status or alertness, anxiety/depression, sleepiness, difficulty speaking, impaired balance, dizziness, confusion, forgetfulness, difficulty concentrating, inability to fall asleep or stay asleep,tingling sensation, bruising, shaking, abnormal or blurry vision, double vision, hearing impairment, shortness of breath, cough, blood clot in the legs, fluid retention, swollen legs, diarrhoea, stomach or abdominal pain, heartburn, upset stomach, difficulty swallowing, dry mouth, skin irritation or redness, dry skin, itching, muscle weakness, painful joints, muscle aches and pains, frequent urination, difficulty with holding your urine, allergic reaction, fever, radiation injury, face swelling, pain, abnormal taste, abnormal liver function tests. 
Česte (mogu se javiti u do 1 na 10 osoba): infekcije usne šupljine, infekcija rane, smanjen broj krvnih stanica (neutropenija, trombocitopenija, limfopenija, leukopenija), povišena razina šećera u krvi, gubitak tjelesne težine, promjena psihičkog stanja ili budnosti, tjeskoba/depresija, pospanost, otežan govor, poremećaj ravnoteže, omaglica, smetenost, zaboravljivost, poteškoće s koncentracijom, nemogućnost da bolesnik zaspi ili spava, trnci, stvaranje modrica, drhtanje, poremećen ili zamagljen vid, dvostruke slike, oštećenje sluha, nedostatak zraka, kašalj, krvni ugrušak u nogama, zadržavanje tekućine, otečene noge, proljev, bol u želucu ili trbuhu, žgaravica, želučane tegobe, otežano gutanje, suha usta, nadraženost ili crvenilo kože, suha koža, svrbež, mišićna slabost, bolni zglobovi, bol u mišićima, učestalo mokrenje, poteškoće sa zadržavanjem urina, alergijska reakcija, vrućica, ozljeda zbog zračenja, oticanje lica, bol, promjena osjeta okusa, odstupanja od normalnih vrijednosti testova funkcije jetre.
For patients with significant liver function abnormalities, physicians should assess the benefit/risk of continuing treatment. 
liječnici trebaju procijeniti omjer koristi/rizika za nastavak liječenja.
Cases of increased bilirubin, problems with bile flow (cholestasis), hepatitis and injury to the liver, including fatal liver failure, have been uncommonly reported. 
Manje često zabilježeni su slučajevi povišene razine bilirubina, poteškoće s protokom žuči (kolestaza) , hepatitis i oštećenje jetre, uključujući zatajenje jetre sa smrtnim ishodom.
Temozolomide Teva contains lactose 
Temozolomid Teva sadrži laktozu
Hepatic injury, including fatal hepatic failure, has been reportedin patients treated with TMZ (see section 4.8). 
Oštećenje jetre, uključujući zatajenje jetre sa smrtnim ishodom, prijavljeno je u bolesnika liječenih TMZ-om (vidjeti dio 4.8).
Temozolomide Teva should only be prescribed by physicians experienced in the oncological treatment of brain tumours. 
4.2 Doziranje i način primjene Temozolomid Teva smiju propisivati samo liječnici s iskustvom u onkološkom liječenju tumora mozga.
Temozolomide Teva may make you feel tired or sleepy. 
Temozolomid Teva može uzrokovati umor ili pospanost.
The other ingredients are: capsule content: lactose, colloidal anhydrous silica, sodium starch glycolate type A, tartaric acid, stearic acid (see section 2 “Temozolomide Teva contains lactose”). 
Sadržaj kapsule: laktoza, koloidni, bezvodni silicijev dioksid, natrijev škroboglikolat, vrste A, tartaratna kiselina, stearatna kiselina (pogledajte dio 2 "Temozolomid Teva sadrži laktozu").
Hepatic enzymes increased, Gamma GT increased, AST increased 
Povišene vrijednosti jetrenih enzima, povišene vrijednosti gama-GT-a, povišene vrijednosti AST-a
After oral administration of 14C-labelled TMZ, mean faecal excretion of 14C over 7 days post-dose was 0.8% 
Nakon peroralne primjene temozolomida označenog radioizotopom 14C, u fecesu je tijekom 7 dana nakon primjene doze izlučeno prosječno 0,8% radioizotopa 14C, što ukazuje na potpunu apsorpciju.
Figure 1 Kaplan-Meier curves for overall survival (intent-to-treat population) The results from the trial were not consistent in the subgroup of patients with a poor performance status (WHO PS=2, n=70), where overall survival and time to progression were similar in both arms. 
Slika 1. Kaplan-Meierove krivulje ukupnog preživljenja (populacija koju se namjeravalo liječiti) Rezultati ispitivanja nisu bili konzistentni u podskupini bolesnika s lošim izvedbenim statusom (SZO
Temozolomide Teva in combination treatment with radiotherapy in newly-diagnosed glioblastoma 
Temozolomid Teva u kombinaciji sa zračenjem u liječenju novodijagnosticiranog multiformnog glioblastoma
† Including cases with fatal outcome *Frequencies estimated based on relevant clinical trials 
*Učestalost procijenjena na temelju relevantnih kliničkih studija
Very common (may affect more than 1 in 10 people): reduced number of blood cells (neutropenia or lymphopenia, thrombocytopenia), loss of appetite, headache, vomiting, nausea (feeling sick in your stomach), constipation (difficulty passing stools). 
Vrlo česte (mogu se javiti u više od 1 na 10 osoba): smanjen broj krvnih stanica (neutropenija ili limfopenija, trombocitopenija), gubitak teka, glavobolja, povraćanje, mučnina (loše osjećanje u želucu), zatvor (otežano pražnjenje crijeva).
How to store Temozolomide Teva 
Kako čuvati Temozolomid Teva
Patients in the TMZ + RT arm received concomitant TMZ (75 mg/m²) once daily, starting the first day of RT until the last day of RT, for 42 days (with a maximum of 49 days). 
Bolesnici u skupini TMZ + RT su od prvog do zadnjeg dana radioterapije tijekom 42 dana (najdulje 49 dana) jedanput na dan primali i TMZ (75 mg/m2).
TMZ was administered as salvage therapy in the follow-up phase in 161 patients of the 282 (57%) in the RT alone arm, and 62 patients of the 277 (22%) in the TMZ + RT arm. 
161 od 282 bolesnika (57%) u skupini u kojoj se primijenila samo RT te u 62 od 277 bolesnika (22%) u skupini koja je uz RT primala i TMZ.
Temozolomide Teva 5 mg hard capsules Temozolomide Teva 20 mg hard capsules Temozolomide Teva 100 mg hard capsules Temozolomide Teva 140 mg hard capsules Temozolomide Teva 180 mg hard capsules Temozolomide Teva 250 mg hard capsules 
Temozolomid Teva 5 mg tvrde kapsule Temozolomid Teva 20 mg tvrde kapsule Temozolomid Teva 100 mg tvrde kapsule Temozolomid Teva 140 mg tvrde kapsule Temozolomid Teva 180 mg tvrde kapsule Temozolomid Teva 250 mg tvrde kapsule
TMZ has minor influence on the ability to drive and use machines due to fatigue and somnolence (see sections 4.8). 
TMZ malo utječe na sposobnost upravljanja vozilima i rada sa strojevima zbog umora i somnolencije
Titanium dioxide (E171) Sunset yellow FCF Aluminium Lake (E110) 
Tinta za označavanje šelak propilenglikol titanijev dioksid (E171) sunset yellow FCF aluminium lake (E110)
Following oral administration, approximately 5% to 10% of the dose is recovered unchanged in the urine over 24 hours, and the remainder excreted as temozolomide acid, 5-aminoimidazole-4carboxamide (AIC) or unidentified polar metabolites. 
Nakon peroralne primjene se približno 5 do 10% doze nalazi u mokraći u nepromijenjenom obliku tijekom 24 sata, dok se ostatak izlučuje u obliku temozolomidske kiseline,
Summary of events reported with temozolomide in the post-marketing setting* Infections and infestations* 
Tablica 6. Sažetak štetnih događaja prijavljenih nakon stavljanja temozolomida u promet* Poremećaji krvi i limfnog sustava
Contains lactose, sunset yellow FCF (E110). 
Sadrži laktozu, sunset yellow FCF (E110).
Temozolomide Teva 5 mg 
Temozolomid Teva 5 mg
Table 4: Treatment-emergent events during concomitant and monotherapy treatment phases in patients with newly-diagnosed glioblastoma multiforme System organ class 
Tablica 4. Štetni događaji koji su se pojavili tijekom faze istodobnog liječenja i faze monoterapije u bolesnika s novodijagnosticiranim multiformnim glioblastomom
- if you have low counts of red blood cells (anaemia), white blood cells and platelets, or blood clotting problems before starting the treatment, or if you develop them during treatment. 
Liječnik će detaljno pregledati bolesnike prije početka liječenja kako bi se utvrdilo postoje li znakovi ove infekcije. - ako imate smanjen broj crvenih krvnih stanica (anemiju), bijelih krvnih stanica i trombocita ili problema sa zgrušavanjem krvi prije početka liječenja, ili se ti poremećaji razviju tijekom liječenja.
Temozolomide Teva 20 mg 
Temozolomid Teva 20 mg
Hyperglycaemia, weight decreased Weight decreased 
Hiperglikemija, smanjenje tjelesne težine
Temozolomide Teva 250 mg 
Temozolomid Teva 250 mg
Propylene Glycol Red iron oxide (E172) Yellow iron oxide (E172) Titanium dioxide (E171) 
Tinta za označavanje šelak propilenglikol željezov oksid, crveni (E172) željezov oksid, žuti (E172) titanijev dioksid (E171)
Patients with newly-diagnosed glioblastoma multiforme If you are a newly-diagnosed patient, treatment will occur in two phases: - treatment together with radiotherapy (concomitant phase) first - followed by treatment with only Temozolomide Teva (monotherapy phase). 
Ako ste novodijagnosticirani bolesnik, liječenje će se odvijati u dvije faze: - prvo liječenje zajedno sa zračenjem (faza istodobnog liječenja)
Dermatitis, dry skin, erythema, pruritus 
Dermatitis, suha koža, eritem, pruritus Suha koža, pruritus
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
UVJETI ILI OGRANIČENJA VEZANI UZ SIGURNU I UČINKOVITU PRIMJENU LI JEK
However, all patients receiving TMZ, particularly patients receiving steroids, should be observed closely for the development of PCP, regardless of the regimen. 
Međutim, sve bolesnike koji primaju TMZ, a osobito bolesnike koji primaju steroide,
- if certain kinds of blood cells are severely reduced (myelosuppression), such as your white blood cell count and platelet count. 
- ako imate jako smanjen broj određenih vrsta krvnih stanica (mijelosupresiju), primjerice leukocita ili trombocita.
Temozolomide Teva 20 mg hard capsules Temozolomide Teva 100 mg hard capsules Temozolomide Teva 140 mg hard capsules Temozolomide Teva 180 mg hard capsules Temozolomide Teva 250 mg hard capsules temozolomide 
Temozolomid Teva 20 mg tvrde kapsule Temozolomid Teva 100 mg tvrde kapsule Temozolomid Teva 140 mg tvrde kapsule Temozolomid Teva 180 mg tvrde kapsule Temozolomid Teva 250 mg tvrde kapsule temozolomid
At 6 months, the fraction of surviving patients was significantly higher in the TMZ arm (60 %) compared with the procarbazine arm (44%) (chi-square p = 0.019). 
(60%) nego u skupini bolesnika koji su primali prokarbazin (44%) (hi-kvadrat p = 0,019).
Blood and lymphatic system disorders Very rare: 
Poremećaji krvi i limfnog sustava Vrlo često:
- if you have nausea (feeling sick in your stomach) and/or vomiting which are very common side effects of Temozolomide Teva (see section 4), your doctor may prescribe you a medicine (an anti-emetic) to help prevent vomiting. 
- ako imate mučninu i/ili povraćanje što su vrlo česte nuspojave lijeka Temozolomid Teva (pogledajte dio 4) liječnik Vam može propisati lijek koji sprečava povraćanje (antiemetik). - ako često povraćate prije ili za vrijeme liječenja, upitajte svog liječnika u koje je vrijeme najbolje uzimati Temozolomid Teva dok povraćanje ne bude pod kontrolom.
Rats appear to be particularly sensitive to oncogenic effects of TMZ, with the occurrence of first tumours within 3 months of initiating dosing. 
TMZ-a, a prvi tumori se pojavljuju u roku od 3 mjeseca nakon početne doze.
prolonged pancytopenia, aplastic anaemia† Neoplasm benign, malignant and unspecified Very rare: 
dugotrajna pancitopenija, aplastična anemija† Dobroćudne, zloćudne i nespecificirane novotvorine
Temozolomide Teva 140 mg 
Temozolomid Teva 140 mg
Indigo carmine (E132) aluminium lake 
Tinta za označavanje šelak propilenglikol indigo carmine (E132) aluminium lake
Temozolomide Teva 180 mg 
Temozolomid Teva 180 mg
Pneumonia, upper respiratory infection, nasal congestion 
Pneumonija, infekcija gornjih dišnih puteva, kongestija nosa
Febril neutropenia, thrombocytopenia, anaemia, leukopenia 
Febrilna neutropenija, trombocitopenija, anemija, leukopenija
Constipation, nausea, vomiting 
Konstipacija, mučnina, povraćanje
Excipients with known effect Each hard capsule contains 72 mg of lactose and sunset yellow FCF (E110). 
Jedna tvrda kapsula sadrži 72 mg laktoze i sunset yellow FCF (E110).
Temozolomide Teva contains sunset yellow FCF (E110) 
Temozolomid Teva sadrži sunset yellow FCF (E110)
TMZ is administered orally at a dose of 75 mg/m² daily for 42 days concomitant with focal radiotherapy (60 Gy administered in 30 fractions). 
TMZ se primjenjuje peroralno u dozi od 75 mg/m2 na dan tijekom 42 dana uz istodobnu radioterapiju
absent or heavy menstrual periods, vaginal irritation, breast pain, hot flushes, shivering, discolouration of your tongue, change in your sense of smell, thirst, tooth disorder. 
nadraženost rodnice, bol u dojkama, navale vrućine, drhtavica, promjena boje jezika, promjena osjeta mirisa, žeđ, promjene na zubima.
Anxiety, emotional lability, insomnia Anxiety, depression, emotional lability, insomnia 
Anksioznost, depresija, emocionalna labilnost, nesanica
Temozolomide Teva 100 mg 
Temozolomid Teva 100 mg
Temozolomide Teva hard capsules should be administered in the fasting state. 
Temozolomid Teva tvrde kapsule moraju se uzimati natašte.
During the monotherapy phase, the dose and way you take Temozolomide Teva will be different. 
Doza i način uzimanja lijeka Temozolomid Teva u fazi monoterapije razlikovat će se od prethodne faze.
Talk to your doctor, pharmacist or nurse before taking Temozolomide Teva. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Temozolomid Teva, - jer će Vas se morati pomno nadzirati zbog moguće pojave teškog oblika upale pluća uzrokovane s Pneumocystis jirovecii.
Titanium dioxide (E171) Yellow iron oxide (E172) Indigo carmine (E132) aluminium lake 
Tinta za označavanje šelak propilenglikol titanijev dioksid (E171) željezov oksid, žuti (E172). indigo carmine (E132) aluminium lake
Temozolomide Teva 5 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, Indigo carmine (E132) aluminium lake, yellow iron oxide (E172) Temozolomide Teva 20 mg hard capsules: (including printing ink): gelatine, titanium dioxide (E171), shellac, propylene glycol, Sunset yellow FCF Aluminium Lake (E110) Temozolomide Teva 100 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), red iron oxide (E172), shellac, propylene glycol and yellow iron oxide (E172). 
Temozolomid Teva 20 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, sunset yellow FCF aluminium lake (E110) Temozolomid Teva 100 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), crveni željezov oksid (E172) šelak, propilenglikol i žuti željezov oksid (E172).
Skin and subcutaneous tissue disorders Very rare: 
Poremećaji kože i potkožnog tkiva Vrlo često:
absolute neutrophil count ≥ 1.5 x 109/l; thrombocyte count ≥ 100 x 109/l; CTC non-haematological toxicity ≤ Grade 1 (except for alopecia, nausea, vomiting). 
a: Istodobno liječenje temozolomidom može se nastaviti kada su zadovoljeni svi sljedeći uvjeti: apsolutni broj neutrofila ≥ 1,5 x 109/l; broj trombocita ≥ 100 x 109/l; nehematološka toksičnost prema CTC ≤ stupnju 1 (osim alopecije, mučnine i povraćanja).
Grade 3 or 4 thrombocytopenia and neutropenia occurred in 19% and 17% respectively, of patients treated for malignant glioma. 
Laboratorijski nalazi Trombocitopenija stupnja 3 ili 4 razvila se u 19%, a neutropenija stupnja 3 ili 4 u 17% bolesnika liječenih zbog malignog glioma, što je dovelo do hospitalizacije i/ili obustave liječenja TMZ-om u 8% odnosno 4% bolesnika.
In patients previously untreated with chemotherapy, TMZ is administered orally at a dose of 200 mg/m² once daily for the first 5 days followed by a 23 day treatment interruption (total of 28 days). 
U bolesnika koji prethodno nisu liječeni kemoterapijom, TMZ se primjenjuje peroralno u dozi od 200 mg/m2 jedanput na dan tijekom prvih 5 dana, nakon čega slijede
Temozolomide Teva 5 mg two stripes in green ink on the cap and “T 5 mg” in green ink on the body 
Temozolomid Teva 5 mg dvije zelene linije na kapici i zelena oznaka “T 5 mg” na tijelu kapsule
Temozolomide Teva 20 mg two stripes in orange ink on the cap and “T 20 mg” in orange ink on the body 
Temozolomid Teva 20 mg dvije narančaste linije na kapici i narančasta oznaka “T 20 mg” na tijelu kapsule
Uncommon (may affect up to 1 in 100 people): flu-like symptoms, red spots under the skin, low potassium level in the blood, weight gain, mood swings, hallucination and memory impairment, partial paralysis, impaired coordination, impaired sensations, partial loss of vision, dry or painful eyes, deafness, infection of the middle ear, ringing in the ears, earache, palpitations (when you can feel your heart beat), blood clot in the lung, high blood pressure, pneumonia, inflammation of your sinuses, bronchitis, a cold or the flu, swollen stomach, difficulty controlling your bowel movements, haemorrhoids, peeling skin, increased skin sensitivity to sunlight, change in skin colour, increased sweating, muscle damage, back pain, difficulty in urinating, vaginal bleeding, sexual impotence, 
suhe ili bolne oči, gluhoća, infekcija srednjeg uha, zvonjava u ušima, bol u uhu, palpitacije (lupanje srca), krvni ugrušak u plućima, visok krvni tlak, upala pluća, upala sinusa, bronhitis, prehlada ili gripa, oticanje trbuha, poteškoće s kontroliranjem stolice, hemoroidi, ljuštenje kože, povećana osjetljivost kože na sunčevu svjetlost, promjena boje kože, pojačano znojenje, oštećenje mišića, bol u leđima, poteškoće s mokrenjem, vaginalno krvarenje, impotencija, izostanak ili obilne menstruacije,
Common (may affect up to 1 in 10 people): loss of weight, tiredness, dizziness, tingling sensation, shortness of breath, diarrhoea, abdominal pain, upset stomach, rash, itching, hair loss, fever, weakness, shivering, feeling unwell, pain, change in taste. 
Česte (mogu se javiti u do 1 na 10 osoba): gubitak tjelesne težine, umor, omaglica, trnci, nedostatak zraka, proljev, bol u trbuhu, želučane tegobe, osip, svrbež, gubitak kose, vrućica, slabost, drhtavica,
CTC Grade 4b a: 
CTC stupanj 4b a: doze TMZ-a navedene su u Tablici 2. b: TMZ se mora prekinuti:
Marketing Authorization Holder 
NOSITELJ ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET
Each capsule is approximately 19.5 mm in length. 
Svaka je kapsula duljine od oko 19,5 mm.
Each capsule is approximately 22 mm in length. 
Svaka je kapsula duljine od oko 22 mm.
Excipient with known effect Each hard capsule contains 117 mg of lactose. 
Jedna tvrda kapsula sadrži 117 mg laktoze.
Each capsule is approximately 16 mm in length. 
Svaka je kapsula duljine od oko 16 mm.
Excipient with known effect Each hard capsule contains 209 mg of lactose. 
Jedna tvrda kapsula sadrži 209 mg laktoze.
Red iron oxide (E172) 
šelak propilenglikol željezov oksid, crveni (E172)
Once escalated, the dose remains at 200 mg/m² per day for the first 5 days of each subsequent cycle except if toxicity occurs. 
Kad se jednom poveća, doza ostaje na razini od 200 mg/m2 na dan tijekom prvih 5
Asthenia, face oedema, pain, condition aggravated, rigors, tooth disorder, 
Astenija, edem lica, bol, pogoršanje stanja, tresavica, promjene na zubima
Temozolomide Teva 5 mg hard capsules 
Temozolomid Teva 5 mg tvrde kapsule
Abdominal distension, fecal incontinence, gastrointestinal disorder (NOS), gastroenteritis, haemorrhoids 
Abdominalna distenzija, inkontinencija stolice, nespecificirani gastrointestinalni poremećaj,
Visual acuity reduced, eye pain, eyes dry 
Smanjena oštrina vida, bol u oku,
Temozolomide Teva 250 mg hard capsules 
Temozolomid Teva 250 mg tvrde kapsule
Each capsule is approximately 18 mm in length. 
Svaka je kapsula duljine od oko 18 mm.
Temozolomide Teva 250 mg hard capsules Each hard capsule contains 250 mg temozolomide. 
Temozolomid Teva 250 mg tvrde kapsule Jedna tvrda kapsula sadrži 250 mg temozolomida.
Hearing impairment 
oštećenje sluha
Temozolomide Teva 20 mg hard capsules 
Temozolomid Teva 20 mg tvrde kapsule
Temozolomide Teva 140 mg hard capsules 
Temozolomid Teva 140 mg tvrde kapsule
CTC Non-haematological Toxicity (except for alopecia, nausea, vomiting) 
CTC stupanj nehematološke toksičnosti (osim alopecije, mučnine i povraćanja) CTC stupnja 2
Temozolomide Teva 20 mg hard capsules: Each capsule contains 20 mg temozolomide. 
Temozolomid Teva 20 mg tvrde kapsule: jedna kapsula sadrži 20 mg temozolomida.
Temozolomide Teva 5 mg hard capsules Each hard capsule contains 5 mg temozolomide. 
Temozolomid Teva 5 mg tvrde kapsule Jedna tvrda kapsula sadrži 5 mg temozolomida.
Temozolomide Teva 140 mg hard capsules: Each capsule contains 140 mg temozolomide. 
Temozolomid Teva 140 mg tvrde kapsule: jedna kapsula sadrži 140 mg temozolomida.
The hard capsules have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body. 
Tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crne linije na kapici i crnom oznakom "T 250 mg" na tijelu kapsule.
Temozolomide Teva 250 mg hard capsules have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body. 
Temozolomid Teva 250 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije crne linije na kapici te crnom oznakom „T 250 mg“ na tijelu kapsule.
Temozolomide Teva 250 mg hard capsules: (including printing ink): gelatin, titanium dioxide (E171), shellac, propylene glycol, black iron oxide (E172), Ammonium hydroxide (E527). 
Temozolomid Teva 250 mg tvrde kapsule: (uključujući tintu za označavanje): želatina, titanijev dioksid (E171), šelak, propilenglikol, crni željezov oksid (E172).
Sodium starch glycolate Type A Colloidal anhydrous silica Tartaric acid 
Sadržaj kapsule laktoza natrijev škroboglikolat, vrste A silicijev dioksid, koloidni, bezvodni tartaratna kiselina stearatna kiselina
Temozolomide Teva 180 mg hard capsules: Each capsule contains 180 mg temozolomide. 
Temozolomid Teva 180 mg tvrde kapsule: jedna kapsula sadrži 180 mg temozolomida.
Excipient with known effect Each hard capsule contains 87 mg of lactose. 
Jedna tvrda kapsula sadrži 87 mg laktoze.
Temozolomide Teva 250 mg hard capsules: Each capsule contains 250 mg temozolomide. 
Temozolomid Teva 250 mg tvrde kapsule: jedna kapsula sadrži 250 mg temozolomida.
Temozolomide Teva 5 mg hard capsules Temozolomide 
Temozolomid Teva 5 mg tvrde kapsule temozolomid
Temozolomide Teva 5 mg hard capsules have a white opaque body and cap with two stripes in green ink on the cap and with “T 5 mg” in green ink on the body. 
Temozolomid Teva 5 mg tvrde kapsule imaju bijelo neprozirno tijelo i kapicu, s dvije zelene linije na kapici te zelenom oznakom „T 5 mg“ na tijelu kapsule.
Temozolomide Teva 180 mg hard capsules 
Temozolomid Teva 180 mg tvrde kapsule
Cerebral haemorrhage, hypertension Embolism pulmonary, oedema, oedema peripheral 
Plućna embolija, edem, periferni edem
Temozolomide Teva 100 mg hard capsules 
Temozolomid Teva 100 mg tvrde kapsule
Temozolomide Teva 20 mg hard capsules Temozolomide 
Temozolomid Teva 20 mg tvrde kapsule temozolomid
Temozolomide Teva 5 mg hard capsules: Each capsule contains 5 mg temozolomide. 
Temozolomid Teva 5 mg tvrde kapsule: jedna kapsula sadrži 5 mg temozolomida.
In a 400 subject recurrent glioma data set, Grade 4 neutropenia occurred in 8% of female vs 4% of male subjects and Grade 4 thrombocytopenia in 8% of female vs 3% of male subjects in the first cycle of therapy. 
žena naspram 4% muškaraca, a trombocitopenija stupnja 4 u 8% žena naspram 3% muškaraca.
Excipient with known effect Each hard capsule contains 84 mg of lactose. 
Jedna tvrda kapsula sadrži 84 mg laktoze.
Temozolomide Teva 100 mg hard capsules: Each capsule contains 100 mg temozolomide. 
Temozolomid Teva 100 mg tvrde kapsule: jedna kapsula sadrži 100 mg temozolomida.
Investigations Common: 
Ostale nuspojave:
Temozolomide Teva 250 mg hard capsules Temozolomide 
Temozolomid Teva 250 mg tvrde kapsule temozolomid